SAB Biotherapeutics, Inc.
SABSHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframePart of the healthcare sector, SAB Biotherapeutics, Inc. (SABS) is listed under Biotechnology. Valued at $258.4M, SABS is a micro-cap name in its sector. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials.
Market Cap
$258.4M
Beta
0.58
P/E (TTM)
—
P/E (Fwd)
-2.98
EPS (TTM)
$-1.20
EPS (Fwd)
$-0.95
ROE
-11.3%
ROA
-33.5%
Cash
$102.6M
Total Debt
$5.1M
Free CF
-$28.8M
52W Change
-6.3%
Annual Financials
Cash vs Debt
Where SABS stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, SABS finished 27.98% below its 150-day moving average ($3.61) and 30.11% below its 200-day moving average ($3.72). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SABS overbought or oversold?
At the October 20, 2026 close, SABS's RSI(14) was 27.9, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $102.6M in cash and $5.1M in debt, SABS maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$28.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -11.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With a beta below 0.7, SAB Biotherapeutics, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence SAB Biotherapeutics, Inc.'s trajectory.